Gut bacteria are to blame for the failure of immune checkpoint therapy for ovarian cancer, new UVA Cancer Center research ...

University of Virginia Cancer Center researchers have explained the failure of immune checkpoint therapy for ovarian cancer by discovering how gut bacteria interfere with the treatment.

University of Virginia Cancer Center researchers have explained the failure of immune checkpoint therapy for ovarian cancer by discovering how gut ...

Just a few months after Vir Biotechnology lost an emergency authorization for its COVID-19 antibody, Marianne de Backer ...

A study published in Science Advances reveals a novel strategy that allows tumors to evade the body's immune response ...

Immunotherapy revolutionises cancer treatment by harnessing the immune system, offering targeted therapy with fewer side ...

A study published in Science Advances reveals a novel strategy that allows tumors to evade the body’s immune response ...

Given Sobi's cash flow generation from its hemophilia business and mature product Synagis, the firm ended 2024 with a net debt/EBITDA ratio of 1.6 times. We expect the firm can support this level of ...

We think the strategy to find more effective combination therapies in hematology and build a larger oncology and dermatology portfolio is solid, although we're waiting for key data before assuming the ...

A study published in Science Advances reveals a novel strategy that allows tumors to evade the body's immune response ...

Immunology is the branch of biomedical ... and mechanistic insights reveal pathways to improved functionality of CAR T cells in solid tumors. In December 2024, the NIH Office of Autoimmune Disease ...

IDEAYA Biosciences, Inc. (NASDAQ:IDYA), a $2 billion market cap company specializing in pharmaceutical preparations, announced the appointment of Joshua Bleharski, Ph.D., as its new Chief Financial ...